share_log

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

EyePoint Pharmaceuticals | 4: Statement of changes in beneficial ownership of securities-Director Zaderej Karen L.

EyePoint Pharmaceuticals | 4：持股變動聲明-董事 Zaderej Karen L.
美股SEC公告 ·  07/13 05:04
牛牛AI助理已提取核心訊息
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
On July 11, 2024, Karen L. Zaderej, associated with EyePoint Pharmaceuticals, Inc. (EYPT), completed a transaction to acquire 2,000 shares of the company's common stock at no cost. This transaction was categorized as an exercise or conversion of derivative security, which is typically related to options or warrants being converted into stock. Following this acquisition, Zaderej's direct holdings in EyePoint Pharmaceuticals increased to a total of 4,000 shares of common stock.
2024年7月11日，與eyepoint pharmaceuticals有關的Karen L. Zaderej以零成本完成了收購該公司普通股2000股的交易。該交易被歸類爲衍生證券的行權或轉換，這通常涉及將期權或權證轉換爲股票。在此收購之後，Zaderej在eyepoint pharmaceuticals的直接持股數量增至總共4000股普通股。
2024年7月11日，與eyepoint pharmaceuticals有關的Karen L. Zaderej以零成本完成了收購該公司普通股2000股的交易。該交易被歸類爲衍生證券的行權或轉換，這通常涉及將期權或權證轉換爲股票。在此收購之後，Zaderej在eyepoint pharmaceuticals的直接持股數量增至總共4000股普通股。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    熱議
    美股
    股票代碼最新價升跌幅

    暫無數據

    資訊熱榜
    更新時間